Singapore - Compound Solutions, global distributor of patent-protected TeaCrine, announced several ground-breaking findings from a new human clinical trial.

Performed at the University of Tennessee and the University of Memphis with renowned health, pharmaceutical, and cardiorespiratory/metabolic research programs, the robust randomized, double-blind, placebo-controlled, four-arm crossover study set out to explore the pharmacokinetics and safety of TeaCrine at multiple doses, and when administered with caffeine.

The findings showed: 1) consuming TeaCrine with caffeine enhanced TeaCrine's bioavailability and potency, 2) combining the two ingredients showed an excellent safety profile, as evaluated by repeated measurements across a broad spectrum of clinical safety markers including heart rate and blood pressure (i.e. both of which were unaffected by co-administration).

Previous human research conducted at the Centre for Applied Health Sciences showed that TeaCrine increased feelings of energy, reduced fatigue, and had strong effects on improving focus, concentration, motivation to exercise and libido. This new study not only validates the prior study's findings, but it also shows the addition of caffeine augments these benefits by improving TeaCrine's bioavailability (increased peak levels and total concentration in the blood over time).

Matt Titlow, CEO of Compound Solutions, said, "We're proud to prove clinically what many have noted anecdotally: caffeine and TeaCrine are a complementary, dynamic combination."